BioSpace News Archive

Immorna today announced that the first subject has been dosed in the Company’s First-In-Human (FIH) Phase 1 multi-center study of JCXH-105, a self-replicating RNA (srRNA) vaccine being developed for the prevention of Shingles (Herpes Zoster; HZ).

SK bioscience has announced today the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorization (MA) for SK bioscience’s COVID-19 vaccine SKYCovion™ (brand name in Korea: SKYCovione™) as a primary series for strong immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

Resonetics, a leading medical contract design and manufacturing organization, announced that Kevin D. Kelly will join the company as President and Chief Executive Officer, effective May 30, 2023.

NeoGenomics, Inc. today announced new data supporting its cancer tests and treatment guidance tools will be showcased in five poster presentations at the 2023 American Society of Clinical Oncology Annual Meeting taking place June 2-6 in Chicago, Illinois.

Alterity Therapeutics today announced it has commenced a new Phase 2 clinical trial of ATH434 in patients with Multiple System Atrophy (MSA) and the first patient has been enrolled.

OLON Group announces the start of construction of a new facility at its Rodano site which will be entirely dedicated to managing and producing Ultra-Potent compounds, used for example as payloads and payload-linkers for ADCs, one of the most promising emerging cancer therapies, which combines the effective killing power of small molecule cytotoxins and the highly specific targeting ability of monoclonal antibodies.

Revive Therapeutics Ltd. announced today an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) evaluating the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.

Trevi Therapeutics, Inc. today announced senior management will attend and participate in the following conferences in June.

Inmagene Biopharmaceuticals today announced that management has been invited to participate in the Jefferies Healthcare Conference, which will be held in New York from June 7-9, 2023.

Spectral Medical Inc. today provided an enrollment update on Tigris, the Company’s follow-on study designed to build on knowledge gained from the earlier EUPHRATES trial.